Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis
| Autor: | Giora Z. Feuerstein, Barbara L. Storer, Richard E. Valocik, Paul F. Koster, Michael N. Blackburn, John R. Toomey |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Male
Time Factors medicine.drug_class Low molecular weight heparin Coronary Disease Pharmacology Factor IXa Rats Sprague-Dawley Fibrinolytic Agents Antithrombotic medicine Animals Humans Carotid Artery Thrombosis Enoxaparin Factor IX Blood coagulation test Dose-Response Relationship Drug business.industry Anticoagulant Antibodies Monoclonal Hematology Heparin Heparin Low-Molecular-Weight Rats Disease Models Animal Immunology Blood Coagulation Tests business Enoxaparin sodium Fibrinolytic agent Blood Flow Velocity medicine.drug |
| Zdroj: | Thrombosis research. 100(1) |
| ISSN: | 0049-3848 |
| Popis: | A humanized inhibitory anti-factor IX(a) antibody (SB 249417) has been compared to enoxaparin (Lovenox) in a rat model of arterial thrombosis. Pretreatment of rats with either SB 249417 (3.0 mg/kg, i. v.) or enoxaparin (30.0 mg/kg, i.v. or s.c.) resulted in comparable and significant reductions in thrombus formation. However, the efficacious dose of enoxaparin resulted in >30-fold increase in the aPTT over baseline, while the efficacious dose of SB 249417 prolonged the aPTT by only approximately 3-fold. Additionally, pretreatment with SB 249417 resulted in sustained blood flow and arterial patency throughout the experiment in >80% of rats treated. In contrast |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect